Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Addex Therapeutics
Addex Therapeutics
(ADXN)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
No data
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Fluorodopa f-18
prostatic neoplasms
,
castration-resistant prostatic neoplasms
Dipraglurant
healthy volunteers/patients
,
dystonia
,
blepharospasm
,
parkinson disease
,
dyskinesias
,
drug-induced dyskinesia
Glutamic acid
lung neoplasms
,
neoplasm metastasis
,
neoplasms
,
head and neck neoplasms
,
recurrence
,
carcinoma
,
small cell lung carcinoma
,
adenocarcinoma of lung
,
bronchiolo-alveolar adenocarcinoma
,
non-small-cell lung carcinoma
RASEGLURANT
gastroesophageal reflux
,
peptic esophagitis
,
migraine disorders
D-glutamate
schizophrenia
,
psychotic disorders
Fludeoxyglucose f-18
idiopathic pulmonary fibrosis
,
alzheimer disease
,
neoplasms
,
ovarian neoplasms
,
rheumatoid arthritis
,
atherosclerosis
,
chronic obstructive pulmonary disease
,
lymphoma
,
mantle-cell lymphoma
,
multiple sclerosis
,
lung diseases
,
obstructive lung diseases
,
recurrence
,
melanoma
,
sarcoidosis
,
pneumonia
,
autoimmune diseases
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use